首页> 外文期刊>European journal of cardio-thoracic surgery: Official journal of the European Association for Cardio-thoracic Surgery >Effect of preoperative angiotensin converting enzyme inhibitor or angiotensin receptor blocker use on the frequency of atrial fibrillation after cardiac surgery: a cohort study from the atrial fibrillation suppression trials II and III.
【24h】

Effect of preoperative angiotensin converting enzyme inhibitor or angiotensin receptor blocker use on the frequency of atrial fibrillation after cardiac surgery: a cohort study from the atrial fibrillation suppression trials II and III.

机译:术前使用血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂对心脏手术后房颤发生频率的影响:一项来自房颤抑制试验II和III的队列研究。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Two recent meta-analyses demonstrated that angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) reduce the risk of developing new-onset atrial fibrillation (AF) by nearly 50%. However, the ability of ACEIs or ARBs to prevent postoperative atrial fibrillation (POAF) after cardiac surgery has not been adequately evaluated. Objective: To evaluate the impact of preoperative ACEI or ARB use on the incidence of POAF after cardiac surgery. METHODS: Patients undergoing coronary artery bypass grafting and/or valvular surgery from the (atrial fibrillation suppression trials II and III (AFIST II and III) randomized, controlled trials were evaluated in this cohort evaluation. Data in respect to patient demographics, surgical characteristics, medication utilization and the incidence of POAF (defined as AF lasting at least 5 min in duration documented by telemetry) were all uniformly and prospectively collected as part of AFIST II and III. Multivariate logistic regression was utilized to calculate adjusted odds ratios with 95% confidence intervals. RESULTS: A total of 338 patients were evaluated of which 175 (51.8%) received an ACEI or ARB preoperatively and 163 (48.2%) did not. The study population was 65.7+/-9.1 years of age, 77.8% were male, 11.2% underwent valve surgery, 3.6% had prior AF, 10.1% had heart failure and 84.0 and 37.9% received postoperative beta-blockade and prophylactic amiodarone, respectively. In total, 110 (32.5%) patients developed POAF. Upon multivariate logistic regression, the preoperative use of an ACEI or ARB was not found to be associated with a statistically significant reduction in POAF (adjusted odds ratio; 0.71, 95% CIs 0.42-1.20). CONCLUSIONS: Although preoperative ACEI or ARB use reduced the odds of developing POAF by 29%, this association with not found to be statistically significant. A study with approximately 600 subjects would be needed to discern if ACEIs or ARBs truly impact POAF.
机译:背景:最近的两项荟萃分析表明,血管紧张素转化酶抑制剂(ACEIs)和血管紧张素受体阻滞剂(ARBs)将新发性房颤(AF)的风险降低了近50%。但是,ACEI或ARB在心脏手术后预防术后房颤(POAF)的能力尚未得到充分评估。目的:评估术前ACEI或ARB的使用对心脏手术后POAF发生率的影响。方法:在这项队列评估中,评估了来自(房颤抑制试验II和III(AFIST II和III)(房颤抑制试验II和III),随机对照试验)的接受冠状动脉搭桥术和/或瓣膜手术的患者。作为AFIST II和III的一部分,均统一和前瞻性地收集了药物的利用率和POAF的发生率(定义为AF持续时间至少为5分钟,通过遥测记录),多因素logistic回归用于计算校正后的优势比,置信度为95%结果:总共评估了338例患者,其中175例(51.8%)术前接受了ACEI或ARB,163例(48.2%)未接受手术,研究人群为65.7 +/- 9.1岁,男性为77.8%。 ,分别有11.2%的患者接受了瓣膜手术,3.6%的患者曾接受房颤,10.1%的患者患有心力衰竭,以及84.0和37.9%的患者接受了术后β受体阻滞剂和预防性胺碘酮治疗,总计110例(32.5%)患者患上了POAF。经多因素logistic回归分析,未发现术前使用ACEI或ARB与POAF的统计学显着降低相关(校正比值比; 0.71,95%CIs 0.42-1.20)。结论:尽管术前使用ACEI或ARB可使发生POAF的几率降低29%,但这一关联在统计学上不显着。大约需要研究600名受试者,才能确定ACEI或ARB是否真正影响POAF。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号